First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
about
Hsp90 Inhibitors for the Treatment of Chronic Myeloid LeukemiaInhibition of nm23-H1 gene expression in chronic myelogenous leukemia cells.Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy.Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status.Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study.
P2860
First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
@en
type
label
First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
@en
prefLabel
First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
@en
P2093
P2860
P356
P1476
First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
@en
P2093
Antonio De Leo
Clara Bertuzzi
Pier Paolo Piccaluga
Stefania Paolini
P2860
P304
P356
10.2147/JBM.S13067
P577
2012-11-29T00:00:00Z